127 patients were treated intensively in trials of the AMLSHG and AMLSG. 34 patients received non-intensive therapy and for 10 patients the therapy is unknown. 148 patients carried a mutation at arginine R882. At the time of diagnosis and relapse samples were further sequenced for 54 genes ...
8. Finding out and monitoring MLL gene rearrangement is important in guiding personal therapy regimen and predicting prognosis in AL. 4 B/C method is an available and convenient method for detecting fusion gene with RARα, AML1 or MLL, and could use for Screenning test in AL patients. ...
A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget. 2012;3:490–501. PubMed PubMed Central Google Scholar Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, et al. BCL-B (BCL2L10) is overexpressed in patients suffering ...
Patients with unexplained heart failure, hepatomegaly, nephrotic syndrome, or peripheral neuropathy should be evaluated for primary systemic (amyloid light... RL Comenzo - 《Vrachebnoe Delo》 被引量: 68发表: 1982年 Prognosis of patients with primary systemic amloidosis who present with dominant ...
In conclusion, ICU admission is justified for selected patients with AML. The ICU mortality rate is highly predictable by the acute illness severity score. A 1-year survival is predicted by haematological prognostic factors. 展开 关键词: acute myeloid leukaemia intensive care prognosis mechanical ...
et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood 128, 3113–3124 (2016). CAS PubMed PubMed Central Google Scholar Stoll, G. et al. Calreticulin expression: interaction with the immune infiltrate and im...
LFS (P=0.882 and P=0.484, respectively), while it became a favorable factor for OS (P=0.011) in the patients undergoing allo-HSCT CONCLUSIONS: MLL t-AML had poor prognosis compared with non-MLL t-AML and MLL de novo AML but allo-HSCT might overcome the poor prognosis of MLL t-AML....
Finally, as our conclusions are primarily based on bioinformatics analyses, experimental validation through in vivo and in vitro studies will be essential to confirm the mechanistic role of FLT3 and assess its therapeutic potential, particularly for patients resistant to conventional therapies....
A total of 77 patients (45 ALL and 32 AML) received chemotherapy with a median follow 槻2.5 years. Unexpectedly, we identified children with reciprocal MLL fusions who exhibited relatively favorable outcomes compared with those in children with complex translocations or a single direct MLL fusion ...